M B Liddell1, S Lovestone, M J Owen. 1. Department of Psychological Medicine, University of Wales College of Medicine, Cardiff, UK. liddellmb@cardiff.ac.uk
Abstract
BACKGROUND: Clinicians are increasingly asked by relatives of patients with Alzheimer's disease to advise on their genetic risk of developing Alzheimer's disease in later life. Many clinicians find this a difficult question to answer. AIMS: To provide information for old age psychiatrists wishing to advise relatives of their risk of developing Alzheimer's disease. METHOD: A selective review of the key literature on the genetic epidemiology of Alzheimer's disease. RESULTS: Currently a DNA diagnosis is attainable in some 70% of families with autosomal dominant Alzheimer's disease. In first-degree relatives of most cases, risk is increased some three- or four-fold relative to controls, but only one-third of this is realised in the average life span. Apolipoprotein E genotyping cannot be used as a predictive test and confers only minimal diagnostic benefit. CONCLUSIONS: Pedigrees with familial Alzheimer's disease should be referred to a Regional Centre for Medical Genetics. Accurate risk prediction is not possible in the vast majority of pedigrees with Alzheimer's disease, although it is possible for the psychiatrist to give a rough estimate of the risk, which can reasonably the couched in reassuring terms.
BACKGROUND: Clinicians are increasingly asked by relatives of patients with Alzheimer's disease to advise on their genetic risk of developing Alzheimer's disease in later life. Many clinicians find this a difficult question to answer. AIMS: To provide information for old age psychiatrists wishing to advise relatives of their risk of developing Alzheimer's disease. METHOD: A selective review of the key literature on the genetic epidemiology of Alzheimer's disease. RESULTS: Currently a DNA diagnosis is attainable in some 70% of families with autosomal dominant Alzheimer's disease. In first-degree relatives of most cases, risk is increased some three- or four-fold relative to controls, but only one-third of this is realised in the average life span. Apolipoprotein E genotyping cannot be used as a predictive test and confers only minimal diagnostic benefit. CONCLUSIONS: Pedigrees with familial Alzheimer's disease should be referred to a Regional Centre for Medical Genetics. Accurate risk prediction is not possible in the vast majority of pedigrees with Alzheimer's disease, although it is possible for the psychiatrist to give a rough estimate of the risk, which can reasonably the couched in reassuring terms.
Authors: F Illes; T Bernhardt; K Prell; C Rietz; G Rudinger; L Frölich; W Maier; M Rietschel Journal: Z Gerontol Geriatr Date: 2006-06 Impact factor: 1.281
Authors: Alexander M Kulminski; Konstantin G Arbeev; Kaare Christensen; Eric Stallard; Iva Miljkovic; Michael Barmada; Anatoliy I Yashin Journal: J Gerontol A Biol Sci Med Sci Date: 2012-12-04 Impact factor: 6.053
Authors: M Dash; A Eid; G Subaiea; J Chang; R Deeb; A Masoud; W E Renehan; A Adem; N H Zawia Journal: Neurotoxicology Date: 2016-06-09 Impact factor: 4.294
Authors: Jane S Paulsen; Martha Nance; Ji-In Kim; Noelle E Carlozzi; Peter K Panegyres; Cheryl Erwin; Anita Goh; Elizabeth McCusker; Janet K Williams Journal: Prog Neurobiol Date: 2013-09-11 Impact factor: 11.685